Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3

被引:118
作者
Selvendiran, Karuppaiyah [1 ]
Bratasz, Anna [1 ]
Kuppusamy, M. Lakshmi [1 ]
Tazi, Mia F. [1 ]
Rivera, Brian K. [1 ]
Kuppusamy, Periannan [1 ]
机构
[1] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
关键词
ovarian cancer; hypoxia; STAT3; ROS; cisplatin; taxol; AG490; MULTIPLE-MYELOMA CELLS; ENDOTHELIAL GROWTH-FACTOR; TUMOR OXYGENATION; STAT3; ACTIVATION; OXIDATIVE STRESS; VEGF EXPRESSION; MURINE TUMOR; REDOX STATUS; SPIN-PROBE; CISPLATIN;
D O I
10.1002/ijc.24601
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Signal transducer and activator of transcription 3 (STAT3) is activated in a variety of human cancers, including ovarian cancer. The molecular mechanism by which the STAT3 is activated in cancer cells is poorly understood. We observed that human ovarian xenograft tumors (A2780) in mice were severely hypoxic (pO(2) similar to 2 mmHg). We further observed that hypoxic exposure significantly increased the phosphorylation of STAT3 (pSTAT3) at the Tyr705 residue in A2780 cell line. The pSTAT3 (Tyr705) level was highly dependent on cellular oxygenation levels, with a significant increase at <2% O-2, and without any change in the pSTAT3 (Ser727) or total STAT3 levels. The pSTAT3 (Tyr705) elevation following hypoxic exposure could be reversed within 12 hr after returning the cells to normoxia. The increased level of pSTAT3 was partly mediated by increased levels of reactive oxygen species generation in the hypoxic cancer cells. Conventional chemotherapeutic drugs cisplatin and taxol were far less effective in eliminating the hypoxic ovarian cancer cells suggesting a role for pSTAT3 in cellular resistance to chemotherapy. Inhibition of STAT3 by AG490 followed by treatment with cisplatin or taxol resulted in a significant increase in apoptosis suggesting that hypoxia-induced STAT3 activation is responsible for chemoresistance. The results have important clinical implications for the treatment of hypoxic ovarian tumors using STAT3-specific inhibitors. (C) 2009 UICC
引用
收藏
页码:2198 / 2204
页数:7
相关论文
共 43 条
[1]
Barton BE, 2004, MOL CANCER THER, V3, P11
[2]
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells [J].
Bhardwaj, Anjana ;
Sethi, Gautam ;
Vadhan-Raj, Saroj ;
Bueso-Ramos, Carlos ;
Takada, Yasunari ;
Gaur, Upasna ;
Nair, Asha S. ;
Shishodia, Shishir ;
Aggarwal, Bharat B. .
BLOOD, 2007, 109 (06) :2293-2302
[3]
BHIMANI RS, 1993, CANCER RES, V53, P4528
[4]
Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin [J].
Bratasz, A ;
Weir, NM ;
Parinandi, NL ;
Zweier, JL ;
Sridhar, R ;
Ignarro, LJ ;
Kuppusamy, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (10) :3914-3919
[5]
In vivo imaging of changes in tumor oxygenation during growth and after treatment [J].
Bratasz, Anna ;
Pandian, Ramasamy P. ;
Deng, Yuanmu ;
Petryakov, Sergey ;
Grecula, John C. ;
Gupta, Nilendu ;
Kuppusamy, Periannan .
MAGNETIC RESONANCE IN MEDICINE, 2007, 57 (05) :950-959
[6]
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols [J].
Bratasz, Anna ;
Selvendiran, Karuppaiyah ;
Wasowicz, Tomasz ;
Bobko, Andrey ;
Khramtsov, Valery V. ;
Ignarro, Louis J. ;
Kuppusamy, Periannan .
JOURNAL OF TRANSLATIONAL MEDICINE, 2008, 6 (1)
[7]
Stat proteins and oncogenesis [J].
Bromberg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) :1139-1142
[8]
Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[9]
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies [J].
Brown, JM .
MOLECULAR MEDICINE TODAY, 2000, 6 (04) :157-162
[10]
Exploiting tumour hypoxia in cancer treatment [J].
Brown, JM ;
William, WR .
NATURE REVIEWS CANCER, 2004, 4 (06) :437-447